Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy ...

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new ...

A significant deal on weight loss drug collapsed in less than two months of its commitment, sparking a spat between Danish ...

Novo Nordisk was previously sued in 2023, along with competitor Eli Lilly, by a patient with severe gastrointestinal side effects after taking Ozempic and Lily's Mounjaro.

Novo Nordisk has been selling Levemir in the US for nearly 20 years, and in March 2023 – under pressure from US lawmakers scrutinising the cost of insulin products in the US marketplace ...

Novo Nordisk said on Monday the European drugs regulator will allow a label update for its diabetes drug Ozempic to include a ...

1 Day NOVO.B -3.93% DJIA -0.25% S&P 500 0.00% Health Care/Life Sciences -0.91% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Novo Nordisk A/S (NVO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation Business Wire Jun 25, 2025, 1:00:00 PM ...

Find out if Novo Nordisk AS ADR (NVO:XNYS) stock is overpriced or undervalued based on Morningstar's evaluation. Assess the current comparison of market prices to the Fair Value of the company's ...

Novo Nordisk A/S (NVO) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings.